Education as a Vaccine (EVA) is a non-profit, youth-focused organisation, founded in 2000. It is committed to advancing the health and rights of children, adolescents, and young people in Nigeria. EVA works through community-led approaches, policy advocacy, and strategic partnerships to address public health challenges, including viral hepatitis.
Education as a Vaccine (EVA) plays a central role in the national coordination of hepatitis elimination efforts in Nigeria. Serving as the Secretariat for the National Steering Committee on Hepatitis, EVA ensures strategic alignment and stakeholder engagement across both federal and state levels. As the fiscal host for project implementation in Gombe State, EVA supports DAPHO (another Nigerian member of ours) in managing state-level activities, particularly those led by the Community Advisory Board. We also coordinate the shipment and delivery of low dead space syringes and needles (LDSSN) and Direct-Acting Antivirals (DAAs) in collaboration with the Federal Government of Nigeria. In addition, EVA ensures compliance with project protocols, provides monitoring and supervision to implementing partners, and works closely with national authorities to promote the scalability and sustainability of hepatitis services across the country.
Hepatitis and PWID/harm reduction
11:35 – 11:40
Chair: WHO – Intro and set the scene.
11:40 – 11:55
Co-chair: EMCDDA – Monitoring viral hepatitis elimination among PWID in Europe.
11:55 – 12:00
ID 29: Ema Pos (not yet registered)
Title: If the mountain won’t come to Mohammed: lessons from a decentralized Infectious Disease consultation.
12:05 – 12:10
ID 152: Brian Conway (Registered in person)
Title: Community Pop-up Clinic: Cascade of Care and HCV Treatment of Vancouver’s inner-city PWID Populations.
12:10 – 12:15
ID 212: Jasmine West (not yet registered)
Title: From lived experience to lived expertise: a syndemic approach.
12:15 – 12:20
ID: 299 Mercy Nyakowa (Registered in person)
Title: HCV and HBV prevalence and associated risk factors among people who inject drugs (PWIDs) in Kenya
12:20 – 12:25
ID: 133 Nalinikanta Rajkumar (Registered in person)
Title: Rapid regimen of HBV vaccination: Does it work for high risk groups?
12:25 – 12:30
Q&A and closing remarks
tHIS
IS
BEN’S
BIG
TEST
effective case finding strategies
Supported by Vir Biotechnology, Inc
During this session you will hear from hepatitis Delta expert, Dr. Maria Buti, and a patient who has lived with hepatitis Delta in a panel discussion moderated by Dr. Carey Hwang, Chief Medical Officer (interim) of Vir Biotechnology. This panel will inform perspectives on patient needs, opportunities for enhanced screening, and strengthening linkages to care.
Session Agenda
14:40 – 14:45
Panel overview and introductions facilitated by Dr Carey Hwang (Vir Biotechnology)
14:45 – 15:05
Panel discussion: Dr Maria Buti (University Hospital Vall d’Hebron, Spain), Milanka Barbosa, Dr Carey Hwang (Chief Medical Officer interim), Vir Biotechnology
15:05 – 15:10
Final remarks and close